Abstract: The present disclosure relates to development and performance of screening methods capable of efficiently identifying candidate lead compounds that bind regulatory RNA oligonucleotides in a sequence-specific manner and exert a biological effect upon such regulatory molecules. Candidate lead compounds possessing RNA binding sequence specificity and targeted biological activity are described, as are approaches for merging structural, NMR-derived data with biological reporter assay results. Compound validation approaches capable of identifying the site(s) of action of such compounds within targeted RNA oligonucleotides are also provided.
Type:
Application
Filed:
April 26, 2018
Publication date:
February 13, 2020
Applicant:
THE RNA MEDICINES COMPANY, INC.
Inventors:
Dalia Cohen, Michelle Markus, Jun Jiang, Michel Guiraldelli, Justin Boyd, Branko Radetich, Nanguneri Nirmala, Johan Pontin
Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
June 20, 2017
Assignee:
THE MEDICINES COMPANY
Inventors:
Dario Lehoux, Thomas Parr, Jr., Gregory Moeck
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Type:
Application
Filed:
February 22, 2017
Publication date:
June 8, 2017
Applicants:
The Medicines Company, AbbVie Inc.
Inventors:
Adel RAFAI FAR, Gopal KRISHNA, Min DING, Sanjay R. CHEMBURKAR, Carl M. KNABLE, James P. PETZEL, Julie J. PRUYNE, Douglas M. REAMER
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
May 16, 2017
Assignees:
THE MEDICINES COMPANY, ABBVIE INC.
Inventors:
Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
Abstract: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.
Type:
Grant
Filed:
October 31, 2013
Date of Patent:
April 4, 2017
Assignee:
THE MEDICINES COMPANY (LEIPZIG) GMBH
Inventors:
Peter Herold, Mohammed Daghish, Stjepan Jelakovic, Friedrich-Alexander Ludwig, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Type:
Application
Filed:
June 21, 2016
Publication date:
October 13, 2016
Applicant:
The Medicines Company
Inventors:
Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Type:
Grant
Filed:
February 22, 2016
Date of Patent:
September 13, 2016
Assignee:
THE MEDICINES COMPANY
Inventors:
Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Type:
Grant
Filed:
March 9, 2013
Date of Patent:
August 30, 2016
Assignee:
The Medicines Company
Inventors:
Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
Abstract: Methods of treating bacterial infections in a subject using oritavancin, including bacteremia, osteomyelitis and endocarditis, are disclosed.
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Type:
Application
Filed:
February 22, 2016
Publication date:
July 14, 2016
Applicant:
The Medicine Company
Inventors:
Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
Abstract: The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1??(I), where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural ?-amino acid or ?-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural ?-amino acid or ?-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.
Type:
Grant
Filed:
January 15, 2004
Date of Patent:
June 14, 2016
Assignee:
The Medicines Company (Leipzig) GmbH
Inventors:
Jörg Stürzebecher, Torsten Steinmetzer, Andrea Schweinitz
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Type:
Grant
Filed:
May 5, 2014
Date of Patent:
April 26, 2016
Assignee:
The Medicines Company
Inventors:
Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
March 29, 2016
Assignee:
THE MEDICINES COMPANY
Inventors:
Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Type:
Application
Filed:
July 16, 2015
Publication date:
January 21, 2016
Applicant:
The Medicines Company
Inventors:
Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James J. Petzel, Julie J. Pruyne, Douglas M. Reamer
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
Type:
Grant
Filed:
December 10, 2013
Date of Patent:
December 29, 2015
Assignee:
THE MEDICINES COMPANY
Inventors:
Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
Abstract: The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2-P1 with P1?(A) and P2?(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events.
Type:
Grant
Filed:
September 13, 2004
Date of Patent:
July 28, 2015
Assignee:
The Medicines Company (Leipzig) GmbH
Inventors:
Jörg Stürzebecher, Torsten Steinmetzer, Andrea Schweinitz, Anne Stürzebecher, Daniel Dönnecke
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.